AMR Action Fund
Vision
Bring 2 to 4 novel antibiotics to patients by 2030.
Approach
The AMR Action Fund is a ground-breaking partnership launched by over 20 leading biopharmaceutical companies, global charitable organizations, and development banks. The aim is to invest over US$1 billion to strengthen and accelerate clinical research of innovative new antibiotics that are addressing the most resistant bacteria and life-threatening infections, as well as provide technical support to biotech companies developing assets in this field. The AMR Action Fund is the largest collaborative venture ever created to address antimicrobial resistance (AMR). The concept of the AMR Action Fund was developed by the IFPMA and its member biopharmaceutical companies, in collaboration with the World Health Organization, the European Investment Bank, and the Wellcome Trust.
CEO:
Henry B. Skinner, PhD
Founders:
Almirall; Amgen; Boehringer Ingelheim; Boehringer Ingelheim Foundation; Chugai; Daiichi-Sankyo; Eisai; Eli Lilly and Company; the European Investment Bank (with the support of the European Commission under Horizon 2020, the 2014-2020 European Union research and innovation program); GlaxoSmithKline; Johnson & Johnson; LEO Pharma; Leaps by Bayer; Lundbeck; Menarini; Merck; Merck KGaA, Darmstadt, Germany; Novartis; Novo Nordisk; Novo Nordisk Foundation; Pfizer; Roche; Shionogi; Takeda; Teva; UCB; and the Wellcome Trust
First investment:
July 2020